These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33570633)

  • 1. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.
    Hamulyák EN; Daams JG; Leebeek FWG; Biemond BJ; Te Boekhorst PAW; Middeldorp S; Lauw MN
    Blood Adv; 2021 Jan; 5(1):113-121. PubMed ID: 33570633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
    De Stefano V; Finazzi G; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):65. PubMed ID: 29946112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
    How J; Story C; Connors JM
    Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of venous thromboembolism in myeloproliferative neoplasms.
    Barbui T; De Stefano V
    Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review.
    Baysal M; Bayrak M; Eşkazan AE
    Expert Rev Hematol; 2023 Feb; 16(2):131-140. PubMed ID: 36709432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.
    Huenerbein K; Sadjadian P; Becker T; Kolatzki V; Deventer E; Engelhardt C; Griesshammer M; Wille K
    Ann Hematol; 2021 Aug; 100(8):2015-2022. PubMed ID: 33216197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
    Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
    Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients.
    How J; Story C; Ren S; Neuberg D; Rosovsky RP; Hobbs GS; Connors JM
    Blood Cancer J; 2021 Nov; 11(11):176. PubMed ID: 34741012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
    De Stefano V; Ruggeri M; Cervantes F; Alvarez-Larrán A; Iurlo A; Randi ML; Elli E; Finazzi MC; Finazzi G; Zetterberg E; Vianelli N; Gaidano G; Rossi E; Betti S; Nichele I; Cattaneo D; Palova M; Ellis MH; Cacciola R; Tieghi A; Hernandez-Boluda JC; Pungolino E; Specchia G; Rapezzi D; Forcina A; Musolino C; Carobbio A; Griesshammer M; Sant'Antonio E; Vannucchi AM; Barbui T
    Leukemia; 2016 Oct; 30(10):2032-2038. PubMed ID: 27113812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
    Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
    J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
    Koschmieder S
    Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
    Finazzi G; De Stefano V; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
    Li A; Garcia DA; Lyman GH; Carrier M
    Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.
    Palareti G; Antonucci E; Legnani C; Mastroiacovo D; Poli D; Prandoni P; Tosetto A; Pengo V; Testa S; Ageno W;
    BMJ Open; 2020 Nov; 10(11):e040449. PubMed ID: 33247017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.